Presently, research is limited to animal studies, and some debates persist, resulting in insufficient clinical evidence to support circadian rhythm regulation or Bmal1-targeted therapies for acute kidney injury and chronic kidney disease. The gene discussed is BMAL1; the disease is acute kidney injury.